Belimumab in the Treatment of Interstitial Lung Disease Associated with Systemic Lupus Erythematosus

Gorthi, Ramya; Attoti, Yeswanth; Atluri, Rama; Mwangi, John

doi:10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6643

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current treatments only reduce the progression of the disease [48]. The choice of a certain immunosuppressive treatment is based on the experience in scleroderma-associated ILD [49].…”

Section: Management Of Ild In Slementioning

confidence: 99%

See 1 more Smart Citation

Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?

Richter

Cardoneanu

Dima

et al. 2023

IJMS

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management.

show abstract

“…Current treatments only reduce the progression of the disease [48]. The choice of a certain immunosuppressive treatment is based on the experience in scleroderma-associated ILD [49].…”

Section: Management Of Ild In Slementioning

confidence: 99%

“…Currently, the impact of biological therapies on patients having various forms of ILD is being investigated [48]. Belimumab, a recombinant monoclonal antibody that targets the B-cell activating factor (BLys), is the first biological agent approved in SLE treatment [54].…”

Section: Management Of Ild In Slementioning

confidence: 99%